Weight-Loss Injections: A Growing Trend Among the Affluent, But Access Remains Unequal
New research indicates a significant uptake of weight-loss injections, such as Mounjaro and Wegovy, among individuals in more affluent areas, even those with lower levels of obesity. Analysis of private prescriptions reveals that women and the middle classes are the most frequent users of these powerful GLP-1 drugs.
A comprehensive study, conducted by The Health Foundation in collaboration with the online weight management provider Voy, examined data from 113,630 patients who received a private prescription between November 2024 and October 2025. The analysis considered various demographic factors, including age, sex, Body Mass Index (BMI), and socioeconomic background.
Key Findings from the Prescription Data:
- Gender Disparity: Nearly 80 per cent of the prescriptions analysed were issued to women.
- Age Profile: The highest rate of uptake for these medications was observed in individuals aged between 30 and 49 years, with a noticeable decline in usage after the age of 60.
- Socioeconomic Divide: A stark disparity emerged when comparing access to these injections based on socioeconomic status. Individuals residing in the most deprived regions were approximately one-third less likely to obtain these jabs compared to those in the least deprived areas. This is particularly concerning given that obesity is twice as prevalent in more disadvantaged communities.
- Treatment Initiation BMI: Among 30 to 49-year-olds in the most deprived areas, around 45 per cent commenced treatment with a BMI of 35 or above. In contrast, this figure was around 30 per cent in the least deprived areas.
Samantha Field, a senior fellow in prevention at The Health Foundation and co-author of the research, expressed concern over these findings. She stated, “The groups bearing the greatest burden of obesity are seeking GLP-1 treatments less frequently, and often at higher BMIs.” This suggests that individuals in more deprived areas may be accessing these medications later in their weight management journey, potentially exposing them to greater health risks in the interim.
Field emphasised the importance of the findings for the National Health Service (NHS) as the rollout of these medications progresses. “The NHS should be taking these findings into account as the rollout of these medications progresses, to ensure they are reaching the people who are most in need of them,” she urged. She also highlighted the broader societal implications, noting, “Ensuring fair public provision is essential, but these medications address a problem that is preventable. It’s more important than ever that government retains focus on making the changes to our food environment that will prevent obesity occurring in the first place.”
The High Cost of Access and its Implications
A significant limitation of the study is its reliance on data from a single provider, Voy. It’s important to acknowledge that different providers offer varying price points and support packages with their prescriptions. For instance, Voy charges between £144 and £324 per month, depending on the specific medication and dosage.
The substantial monthly cost associated with these weight-loss injections is likely a major barrier for individuals in less affluent areas. Study authors suggest that this financial burden may also contribute to a higher likelihood of individuals in these regions discontinuing their medication.
Weight-loss injections, known scientifically as GLP-1 receptor agonists, function by mimicking natural hormones that regulate blood sugar, appetite, and digestion. While they are prescription-only medications, access pathways differ significantly between private healthcare and the NHS.
Accessing Weight-Loss Injections: NHS vs. Private
- NHS Eligibility: To access these drugs on the NHS, patients typically need to have a BMI of 40 or more.
- Private Provider Eligibility: Private providers, however, often offer these medications to individuals with a BMI over 30.
NHS England has initiated a phased, long-term rollout of Mounjaro, planned to extend over a decade. However, current data suggests that even patients who meet the eligibility criteria may face difficulties in obtaining the drug through the NHS.
In the initial three years of the 12-year rollout, approximately 220,000 patients have been prioritised on the NHS. This means that the vast majority of patients requiring Mounjaro are currently opting for private prescriptions. NHS England has previously indicated that if all eligible patients, estimated to be over three million, were to seek the drug within the first year, and 70 per cent of them commenced treatment, the impact on primary care and general practice would be profound, potentially consuming 18 per cent of GP appointments.
Semaglutide (Wegovy), another GLP-1 drug, is also available on the NHS for individuals experiencing health issues linked to their weight and a high BMI.
A spokesperson for the NHS commented, “The NHS is rightly prioritising the rollout of weight-loss drugs for those in the greatest clinical need and is exploring ways to accelerate the offering so that eligible people can benefit from safe and effective treatment wherever they live in England.” They added, “The NHS also offers a wide range of other support for people to lose weight, which has helped tens of thousands of people achieve a healthier weight and wider lifestyle benefits.”
While the effectiveness of these weight-loss injections is evident for many, the current landscape highlights significant inequities in access, with cost and socioeconomic factors playing a crucial role in who can benefit from these advancements in medical treatment.
